Overview

Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Patients with kidney failure have a poor survival rate that is due to a much higher than average rate of heart and vascular disease. The reason that kidney failure causes heart disease is unknown but recent research suggests that a hormone called aldosterone, which is increased in patients with kidney disease may damage the heart and blood vessels. The investigators propose, using a randomized blinded trial, to find out whether drugs that inhibit the actions of aldosterone have beneficial effects on the cardiovascular system in patients with kidney failure
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Birmingham
Collaborator:
British Heart Foundation
Treatments:
Spironolactone